Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

January 2020 | 115 pages | ID: F000538AA63AEN
Global Markets Direct

Abstracts

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2020, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 4, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Fibromyalgia (Fibromyalgia Syndrome) - Overview
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products
Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Astellas Pharma Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cytocom Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by FSD Pharma Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Innovative Med Concepts LLC, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Intec Pharma Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by NeuroCycle Therapeutics Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Vitality Biopharma Inc, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aptinyx Inc
Astellas Pharma Inc
Cytocom Inc
FSD Pharma Inc
H. Lundbeck AS
Innovative Med Concepts LLC
Intec Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Luye Pharma Group Ltd
NeuroCycle Therapeutics Inc
One World Cannabis Ltd
PRISM Pharma Co Ltd
Tetra Bio-Pharma Inc
Teva Pharmaceutical Industries Ltd
Tonix Pharmaceuticals Holding Corp
Vitality Biopharma Inc